Advanced search
Publication Cover
Expert Review of Vaccines Volume 11, 2012 - Issue 5
Submit an article Journal homepage
603
Views
42
CrossRef citations to date
0
Altmetric
Reviews

Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production

Emanuele Montomoli Department of Physiopathology Experimental Medicine and Public Health, University of Siena, Via Aldo Moro 3, 53100 Siena, Italy; Department of Physiopathology Experimental Medicine and Public Health, University of Siena, Via Aldo Moro 3, 53100 Siena, Italy. [email protected]
,
Baharak Khadang Department of Physiopathology Experimental Medicine and Public Health, University of Siena, Via Aldo Moro 3, 53100 Siena, Italy; Department of Physiopathology Experimental Medicine and Public Health, University of Siena, Via Aldo Moro 3, 53100 Siena, Italy
,
Simona Piccirella VisMederi srl, Enterprise of Service in Life Sciences, Via Fiorentina 1, 53100 Siena, Italy; VisMederi srl, Enterprise of Service in Life Sciences, Via Fiorentina 1, 53100 Siena, Italy
,
Claudia Trombetta Department of Physiopathology Experimental Medicine and Public Health, University of Siena, Via Aldo Moro 3, 53100 Siena, Italy; Department of Physiopathology Experimental Medicine and Public Health, University of Siena, Via Aldo Moro 3, 53100 Siena, Italy
,
Elisa Mennitto VisMederi srl, Enterprise of Service in Life Sciences, Via Fiorentina 1, 53100 Siena, Italy; VisMederi srl, Enterprise of Service in Life Sciences, Via Fiorentina 1, 53100 Siena, Italy
,
Ilaria Manini Department of Physiopathology Experimental Medicine and Public Health, University of Siena, Via Aldo Moro 3, 53100 Siena, Italy; Department of Physiopathology Experimental Medicine and Public Health, University of Siena, Via Aldo Moro 3, 53100 Siena, Italy
,
Valerio Stanzani Department of Physiopathology Experimental Medicine and Public Health, University of Siena, Via Aldo Moro 3, 53100 Siena, Italy; Department of Physiopathology Experimental Medicine and Public Health, University of Siena, Via Aldo Moro 3, 53100 Siena, Italy
&
Giulia Lapini Department of Physiopathology Experimental Medicine and Public Health, University of Siena, Via Aldo Moro 3, 53100 Siena, Italy; Department of Physiopathology Experimental Medicine and Public Health, University of Siena, Via Aldo Moro 3, 53100 Siena, Italy
 show all
Pages 587-594 | Published online: 09 Jan 2014

References

  • Luke CJ, Subbarao K. Vaccines for pandemic influenza. Emerging Infect. Dis. 12(1), 66–72 (2006).
  • Michaelis M, Doerr HW, Cinatl J Jr. Chickens and men: avian influenza in humans. Curr. Mol. Med. 9(2), 131–151 (2009).
  • Cumulative Number of Confirmed Human Cases of Avian Influenza A(H5/N1) Reported to WHO. WHO, Geneva, Switzerland (2009).
  • Michaelis M, Doerr HW, Cinatl J Jr. Novel swine-origin influenza A virus in humans: another pandemic knocking at the door. Med. Microbiol. Immunol. 198(3), 175–183 (2009).
  • Kistner O, Barrett PN, Mundt W, Reiter M, Schober-Bendixen S, Dorner F. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 16(9–10), 960–968 (1998).
  • Rowe PM. Pandemic influenza (un) preparedness described. Lancet 346, 1699 (1995).
  • Halperin SA, Smith B, Mabrouk T et al. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine 20(7–8), 1240–1247 (2002).
  • Treanor JJ, Schiff GM, Hayden FG et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA 297(14), 1577–1582 (2007).
  • DuBois RM, Aguilar-Yañez JM, Mendoza-Ochoa GI et al. The receptor-binding domain of influenza virus hemagglutinin produced in Escherichia coli folds into its native, immunogenic structure. J. Virol. 85(2), 865–872 (2011).
  • Mabrouk T, Ellis RW. Influenza vaccine technologies and the use of the cell-culture process (cell-culture influenza vaccine). Dev. Biol. (Basel) 110, 125–134 (2002).
  • Genzel Y, Reichl U. Continuous cell lines as a production system for influenza vaccines. Expert Rev. Vaccines 8(12), 1681–1692 (2009).
  • Audsley JM, Tannock GA. Cell-based influenza vaccines: progress to date. Drugs 68(11), 1483–1491 (2008).
  • Robertson JS, Cook P, Attwell AM, Williams SP. Replicative advantage in tissue culture of egg-adapted influenza virus over tissue-culture derived virus: implications for vaccine manufacture. Vaccine 13(16), 1583–1588 (1995).
  • Use of Cell Lines for the Production of Influenza Virus Vaccines: An Appraisal of Technical, Manufacturing, and Regulatory Considerations. WHO, Geneva, Switzerland (2007).
  • Palache AM, Scheepers HS, de Regt V et al. Safety, reactogenicity and immunogenicity of Madin–Darby canine kidney cell-derived inactivated influenza subunit vaccine. A meta-analysis of clinical studies. Dev. Biol. Stand. 98, 115–125; discussion 133 (1999).
  • Groth N, Montomoli E, Gentile C, Manini I, Bugarini R, Podda A. Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: a sequential Phase I and Phase II clinical trial. Vaccine 27(5), 786–791 (2009).
  • Liu J, Mani S, Schwartz R, Richman L, Tabor DE. Cloning and assessment of tumorigenicity and oncogenicity of a Madin–Darby canine kidney (MDCK) cell line for influenza vaccine production. Vaccine 28(5), 1285–1293 (2010).
  • Romanova J, Katinger D, Ferko B et al. Distinct host range of influenza H3N2 virus isolates in Vero and MDCK cells is determined by cell specific glycosylation pattern. Virology 307(1), 90–97 (2003).
  • Koudstaal W, Hartgroves L, Havenga M et al. Suitability of PER.C6 cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics. Vaccine 27(19), 2588–2593 (2009).
  • McPherson CE. Development of a novel recombinant influenza vaccine in insect cells. Biologicals 36(6), 350–353 (2008).
  • Reisinger KS, Block SL, Izu A, Groth N, Holmes SJ. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity. J. Infect. Dis. 200(6), 849–857 (2009).
  • Pau MG, Ophorst C, Koldijk MH, Schouten G, Mehtali M, Uytdehaag F. The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine 19(17–19), 2716–2721 (2001).
  • Madin SH, Darby NB Jr. Established kidney cell lines of normal adult bovine and ovine origin. Proc. Soc. Exp. Biol. Med. 98(3), 574–576 (1958).
  • Cordat E. Unraveling trafficking of the kidney anion exchanger 1 in polarized MDCK epithelial cells. Biochem. Cell Biol. 84(6), 949–959 (2006).
  • Hussain AI, Cordeiro M, Sevilla E, Liu J. Comparison of egg and high yielding MDCK cell-derived live attenuated influenza virus for commercial production of trivalent influenza vaccine: in vitro cell susceptibility and influenza virus replication kinetics in permissive and semi-permissive cells. Vaccine 28(22), 3848–3855 (2010).
  • Palache AM, Brands R, van Scharrenburg GJ. Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. J. Infect. Dis. 176(Suppl. 1), S20–S23 (1997).
  • Doroshenko A, Halperin SA. Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines). Expert Rev. Vaccines 8(6), 679–688 (2009).
  • Katz JM, Webster RG. Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. J. Infect. Dis. 160(2), 191–198 (1989).
  • Gregersen JP. A risk-assessment model to rate the occurrence and relevance of adventitious agents in the production of influenza vaccines. Vaccine 26(26), 3297–3304 (2008).
  • Szymczakiewicz-Multanowska A, Groth N, Bugarini R et al. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J. Infect. Dis. 200(6), 841–848 (2009).
  • Clark TW, Pareek M, Hoschler K et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N. Engl. J. Med. 361(25), 2424–2435 (2009).
  • Trusheim H, Roth B, Wilms R et al. The MDCK33016-PF cell line is not only suitable for the production of cell based influenza vaccine but also an ideal substrate for influenza virus isolation. Presented at: Options for the Control of Influenza Conference VI. ON, Canada, 17–23 June 2007.
  • Fallaux FJ, Bout A, van der Velde I et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum. Gene Ther. 9(13), 1909–1917 (1998).
  • Lewis JA, Brown EL, Duncan PA. Approaches to the release of a master cell bank of PER.C6 cells; a novel cell substrate for the manufacture of human vaccines. Dev. Biol. (Basel) 123, 165–176, discussion 183–197 (2006).
  • Cox RJ, Madhun AS, Hauge S et al. A Phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine 27(13), 1889–1897 (2009).
  • Ledwith BJ, Lanning CL, Gumprecht LA et al. Tumorigenicity assessments of Per. ER C6 cells and of an Ad5-vectored HIV-1 vaccine produced on this continuous cell line. Dev. Biol. (Basel) 123, 251–263; discussion 265 (2006).
  • Cox MM. Progress on baculovirus-derived influenza vaccines. Curr. Opin. Mol. Ther. 10(1), 56–61 (2008).
  • Brooks SA. Appropriate glycosylation of recombinant proteins for human use: implications of choice of expression system. Mol. Biotechnol. 28(3), 241–255 (2004).
  • Cox MM, Hollister JR. FluBlok, a next generation influenza vaccine manufactured in insect cells. Biologicals 37(3), 182–189 (2009).
  • Treanor JJ, Wilkinson BE, Masseoud F et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19(13–14), 1732–1737 (2001).
  • Kang SM, Song JM, Quan FS, Compans RW. Influenza vaccines based on virus-like particles. Virus Res. 143(2), 140–146 (2009).
  • Kang SM, Yoo DG, Lipatov AS et al. Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS ONE 4(3), e4667 (2009).
  • Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 23(50), 5751–5759 (2005).
  • Bright RA, Carter DM, Crevar CJ et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE 3(1), e1501 (2008).
  • Barrett PN, Portsmouth D, Ehrlich HJ. Developing cell culture-derived pandemic vaccines. Curr. Opin. Mol. Ther. 12(1), 21–30 (2010).
  • Rimmelzwaan GF, McElhaney JE. Correlates of protection: novel generations of influenza vaccines. Vaccine 26(Suppl. 4), D41–D44 (2008).
  • Montagnon BJ, Fanget B, Nicolas AJ. The large-scale cultivation of VERO cells in micro-carrier culture for virus vaccine production. Preliminary results for killed poliovirus vaccine. Dev. Biol. Stand. 47, 55–64 (1981).
  • Sutter RW, Kew OM. Poliovirus vaccine-live. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA, Offit PA (Eds). Saunders Elsevier, PA, USA, 631–685 (2008).
  • Cells, products, safety. Backgrounds papers from the WHO Study Group on Biologicals. Geneva, 18–19 Nov. 1986. Dev. Biol. Stand. 68, 1–81 (1987).
  • Barrett PN, Mundt W, Kistner O, Howard MK. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev. Vaccines 8(5), 607–618 (2009).
  • Kistner O, Howard MK, Spruth M et al. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 25(32), 6028–6036 (2007).
  • Tseng YF, Hu AY, Huang ML et al. Adaptation of high-growth influenza H5N1 vaccine virus in Vero cells: implications for pandemic preparedness. PLoS ONE 6(10), e24057 (2011).
  • Annex 5. In: WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines. WHO, Geneva, Switzerland (2005).
  • Brühl P, Kerschbaum A, Kistner O, Barrett N, Dorner F, Gerencer M. Humoral and cell-mediated immunity to Vero cell-derived influenza vaccine. Vaccine, 19 1149–1158 (2001).
  • Stephenson I. H5N1 vaccines: how prepared are we for a pandemic? Lancet 368(9540), 965–966 (2006).
  • Ehrlich HJ, Müller M, Oh HM et al.; Baxter H5N1 Pandemic Influenza Vaccine Clinical Study Team. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N. Engl. J. Med. 358(24), 2573–2584 (2008).
  • Lin J, Zhang J, Dong X et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a Phase I randomised controlled trial. Lancet 368(9540), 991–997 (2006).
  • Ehrlich HJ, Müller M, Fritsch S et al. A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses. J. Infect. Dis. 200(7), 1113–1118 (2009).
  • Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 459(7249), 931–939 (2009).
  • Mayrhofer J, Coulibaly S, Hessel A et al. Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection. J. Virol. 83(10), 5192–5203 (2009).
  • Barrett PN, Berezuk G, Fritsch S et al. Efficacy, safety, and immunogenicity of a Vero cell culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 377(9767), 751–759 (2011).
  • Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst. Rev. 7, CD001269 (2010).
  • Voordouw AC, Beyer WE, Smith DJ, Sturkenboom MC, Stricker BH. Evaluation of serological trials submitted for annual re-licensure of influenza vaccines to regulatory authorities between 1992 and 2002. Vaccine 28(2), 392–397 (2009).
  • Ambrose CS. Efficacy and correlates of protection for cell culture-derived and egg-derived inactivated influenza vaccines in younger adults. Expert Rev. Vaccines 10(8), 1127–1130 (2011).
  • Bridges CB, Katz JM, Levandowski RA, Cox NJ. Inactivated influenza vaccines. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA, Offit PA (Eds). Saunders Elsevier, PA, USA, 258–290 (2008).
  • Horaud F. Absence of viral sequences in the WHO-Vero Cell Bank. A collaborative study. Dev. Biol. Stand. 76, 43–46 (1992).
  • Furesz J, Fanok A, Contreras G, Becker B. Tumorigenicity testing of various cell substrates for production of biologicals. Dev. Biol. Stand. 70, 233–243 (1989).

Patents

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.